Ionis Pharmaceuticals. has filed a patent for methods, compounds, and compositions that can inhibit the expression of HSD17B13. These inventions can be used for treating, preventing, or improving a disease associated with HSD17B13. GlobalData’s report on Ionis Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Ionis Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ionis Pharmaceuticals, Nucleic acid active pharmaceutical ingredient was a key innovation area identified from patents. Ionis Pharmaceuticals's grant share as of September 2023 was 38%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20230310483A1) describes oligomeric compounds and their use in treating diseases associated with HSD17B13. The patent claims include various oligomeric compounds with specific chemical structures and compositions.

Claims 109, 110, and 111 describe different oligomeric compounds. Claim 109 specifies an oligomeric compound with a particular chemical structure, while claim 110 refers to a similar compound but as a sodium or potassium salt. Claim 111 describes an oligomeric compound consisting of 16 linked nucleosides with a specific nucleobase sequence and modified structure. This compound includes a gap segment, a 5' wing segment, and a 3' wing segment, with specific sugar components and internucleoside linkages.

Claims 112-118 focus on pharmaceutical compositions containing the oligomeric compounds mentioned in claims 109-111. These compositions include the oligomeric compound and a pharmaceutically acceptable diluent, with claim 114, 116, and 118 specifying water as the diluent.

Claims 119-124 describe methods of treating diseases associated with HSD17B13 using the oligomeric compounds mentioned in claims 109-111. These methods involve administering the oligomeric compound to an individual with a specific disease, such as liver disease, NAFLD, NASH, alcoholic steatohepatitis (ASH), alcoholic liver disease, nonalcoholic liver disease, alcoholic cirrhosis, nonalcoholic cirrhosis, steatohepatisis, hepatic steatosis, hepatocellular carcinoma, HCV hepatitis, chronic hepatitis, hereditary hemochromatosis, or primary sclerosing cholangitis.

Overall, this patent application presents various oligomeric compounds and their potential use in treating diseases associated with HSD17B13. The claims cover the chemical structures of the compounds, pharmaceutical compositions containing them, and methods of treatment using these compounds.

To know more about GlobalData’s detailed insights on Ionis Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies